- A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depressionBrendon Binneman
Pfizer Global Research and Development, M S 8260 2604, Groton, CT 06340, USA
Am J Psychiatry 165:617-20. 2008..This study was designed to evaluate the safety and efficacy of CP-316,311, a selective nonpeptide antagonist of corticotropin-releasing hormone type 1 (CRH(1)) receptors, in the treatment of recurrent major depressive disorder...
- Cerebral metabolic effects of intravenous glycine in healthy human subjectsAlexander Neumeister
Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06516, USA
J Clin Psychopharmacol 26:595-9. 2006....